Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works

The Protein Data Bank

Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196 · see citing works

Inflammation and cancer

Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111 · see citing works

Unresponsiveness of MyD88-deficient mice to endotoxin.

Kawai, T., Adachi, O., Ogawa, T., Takeda, K., & Akira, S. (1999) · Immunity · doi:10.1016/s1074-7613(00)80086-2 · Cited by 2,367 · see citing works

Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function.

Adachi, O., Kawai, T., Takeda, K., Matsumoto, M., Tsutsui, H., Sakagami, M., Nakanishi, K., & Akira, S. (1998) · Immunity · doi:10.1016/s1074-7613(00)80596-8 · Cited by 2,358 · see citing works

30 Years of NF-κB: A Blossoming of Relevance to Human Pathobiology

Zhang, Q., Lenardo, M. J., & Baltimore, D. (2017) · Cell · doi:10.1016/j.cell.2016.12.012 · Cited by 1,979 · see citing works

Phthalimide conjugation as a strategy for in vivo target protein degradation

Winter, G. E., Buckley, D. L., Paulk, J., Roberts, J. M., Souza, A., Dhe-Paganon, S., & Bradner, J. E. (2015) · Science · doi:10.1126/science.aab1433 · Cited by 1,760 · see citing works

Oncogenically active MYD88 mutations in human lymphoma

Ngo, V. N., Young, R. M., Schmitz, R., Jhavar, S. G., Xiao, W., Lim, K., Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., et al. (2010) · Nature · doi:10.1038/nature09671 · Cited by 1,514 · see citing works

Induced protein degradation: an emerging drug discovery paradigm

Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486 · see citing works

TRAF6 is a signal transducer for interleukin-1

Cao, Z., Xiong, J., Takeuchi, M., Kurama, T., & Goeddel, D. V. (1996) · Nature · doi:10.1038/383443a0 · Cited by 1,305 · see citing works

Toll-Like Receptor Signaling Pathways

Barton, G. M., & Medzhitov, R. M. (2003) · Science · doi:10.1126/science.1085536 · Cited by 1,270 · see citing works

RCSB Protein Data Bank: biological macromolecular structures enabling research and education in fundamental biology, biomedicine, biotechnology and energy

Burley, S. K., Berman, H. M., Bhikadiya, C., Bi, C., Chen, L., Costanzo, L. D., Christie, C. H., Dalenberg, K., Duarte, J. M., Dutta, S., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky1004 · Cited by 1,249 · see citing works

Helical Assembly in the MyD88-IRAK4-IRAK2 Complex in TLR/IL-1R Signalling

Lin, S.-C., Lo, Y.-C., & Wu, H. (2010) · Nature · doi:10.1038/nature09121 · Cited by 1,111 · see citing works

Genetic and functional drivers of diffuse large B cell lymphoma

Reddy, A., Zhang, J., Davis, N. S., Moffitt, A. B., Love, C. L., Waldrop, A., Leppa, S., Pasanen, A., Meriranta, L., Karjalainen-Lindsberg, M.-L., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.027 · Cited by 1,104 · see citing works

Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4

Suzuki, N., Suzuki, S., Duncan, G. S., Millar, D. G., Wada, T., Mirtsos, C., Takada, H., Wakeham, A. C., Itié, A., Li, S., et al. (2002) · Nature · doi:10.1038/nature736 · Cited by 858 · see citing works

PROteolysis TArgeting Chimeras (PROTACs) — Past, present and future

Pettersson, M., & Crews, C. M. (2019) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2019.01.002 · Cited by 818 · see citing works

Modular PROTAC design for the degradation of oncogenic BCR-ABL

Lai, A. C., Toure, M., Hellerschmied, D., Salami, J., Jaime‐Figueroa, S., Ko, E., Hines, J., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507634 · Cited by 618 · see citing works

Plasticity in binding confers selectivity in ligand-induced protein degradation

Nowak, R. P., DeAngelo, S. L., Buckley, D., He, Z., Donovan, K. A., An, J., Safaee, N., Jedrychowski, M. P., Ponthier, C. M., Ishoey, M., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0055-y · Cited by 615 · see citing works

The interleukin‐1 receptor/Toll‐like receptor superfamily: 10 years of progress

O'Neill, L. A. J. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00701.x · Cited by 612 · see citing works

Protac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?

Churcher, I. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01272 · Cited by 491 · see citing works

IRAK-M Is a Novel Member of the Pelle/Interleukin-1 Receptor-associated Kinase (IRAK) Family*

Wesche, H., Gao, X., Li, X.-X., Kirschning, C., Stark, G., & Cao, Z.-D. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.27.19403 · Cited by 475 · see citing works

Delineating the role of cooperativity in the design of potent PROTACs for BTK

Zorba, A., Nguyen, C., Xu, Y., Starr, J., Borzilleri, K., Smith, J., Zhu, H., Farley, K. A., Ding, W., Schiemer, J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1803662115 · Cited by 419 · see citing works

A multiprotein supercomplex controlling oncogenic signalling in lymphoma

Phelan, J. D., Young, R. M., Webster, D. E., Roulland, S., Wright, G. W., Kasbekar, M., Shaffer, A. L., Ceribelli, M., Wang, J. Q., Schmitz, R., et al. (2018) · Nature · doi:10.1038/s41586-018-0290-0 · Cited by 404 · see citing works

SALL4 mediates teratogenicity as a thalidomide-dependent cereblon substrate

Matyskiela, M. E., Couto, S., Zheng, X., Lu, G., Hui, J., Stamp, K., Drew, C., Ren, Y., Wang, M., Carpenter, A., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0129-x · Cited by 338 · see citing works

The interleukin-1 receptor-associated kinases: Critical regulators of innate immune signalling

Flannery, S. M., & Bowie, A. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.06.020 · Cited by 316 · see citing works

Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation

Cromm, P. M., Samarasinghe, K. T. G., Hines, J., & Crews, C. M. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.8b08008 · Cited by 293 · see citing works

Recurrent Mutations of MYD88 and TBL1XR1 in Primary Central Nervous System Lymphomas

González-Aguilar, A., Idbaïh, A., Boisselier, B., Habbita, N., Rossetto, M., Laurenge, A., Bruno, A., Jouvet, A., Polivka, M., Adam, C., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0845 · Cited by 239 · see citing works

MYD88 L265P mutation in Waldenstrom macroglobulinemia

Poulain, S., Roumier, C., Decambron, A., Renneville, A., Herbaux, C., Bertrand, E., Tricot, S., Daudignon, A., Galiègue‐Zouitina, S., Soenen, V., et al. (2013) · Blood · doi:10.1182/blood-2012-06-436329 · Cited by 235 · see citing works

IRAK-4 as the central TIR signaling mediator in innate immunity.

Suzuki, N., Suzuki, S., & Yeh, W. (2002) · Trends in immunology · doi:10.1016/s1471-4906(02)02298-6 · Cited by 228 · see citing works

IRAK-mediated Translocation of TRAF6 and TAB2 in the Interleukin-1-induced Activation of NFκB

Qian, Y., Commane, M., Ninomiya‐Tsuji, J., Matsumoto, K., & Li, X. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102262200 · Cited by 222 · see citing works

PROTAC-Mediated Degradation of Bruton’s Tyrosine Kinase Is Inhibited by Covalent Binding

Tinworth, C. P., Lithgow, H., Dittus, L., Bassi, Z. I., Hughes, S. E., Muelbaier, M., Dai, H., Smith, I. E. D., Kerr, W. J., Burley, G. A., et al. (2019) · ACS Chemical Biology · doi:10.1021/acschembio.8b01094 · Cited by 195 · see citing works

Essential role of IRAK-4 protein and its kinase activity in Toll-like receptor–mediated immune responses but not in TCR signaling

Kawagoe, T., Sato, S., Jung, A., Yamamoto, M., Matsui, K., Kato, H., Uematsu, S., Takeuchi, O., & Akira, S. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061523 · Cited by 187 · see citing works

The TLR and IL-1 signalling network at a glance

Cohen, P. (2014) · Journal of Cell Science · doi:10.1242/jcs.149831 · Cited by 182 · see citing works

Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma

Montesinos‐Rongen, M., Godlewska, E., Brunn, A., Wiestler, O. D., Siebert, R., & Deckert, M. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0891-2 · Cited by 178 · see citing works

Discovery of Clinical Candidate 1-{[(2 S ,3 S ,4 S )-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design

Lee, K. L., Ambler, C. M., Anderson, D. R., Boscoe, B. P., Bree, A. G., Brodfuehrer, J., Chang, J. S., Choi, C., Chung, S., Curran, K. J., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00231 · Cited by 162 · see citing works

Selective interleukin-1 receptor–associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy

Kelly, P. N., Romero, D. L., Yang, Y., Shaffer, A. L., Chaudhary, D., Robinson, S. D., Miao, W., Rui, L., Westlin, W., Kapeller, R., et al. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20151074 · Cited by 161 · see citing works

Interleukin-1 receptor–associated kinase 4 (IRAK4) plays a dual role in myddosome formation and Toll-like receptor signaling

Nardo, D. D., Balka, K. R., Gloria, Y. C., Rao, V. R., Latz, E., & Masters, S. L. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003314 · Cited by 156 · see citing works

IRAK4 Dimerization and trans -Autophosphorylation Are Induced by Myddosome Assembly

Ferrao, R., Zhou, H., Shan, Y., Liu, Q., Li, Q., Shaw, D. E., Li, X., & Wu, H. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.08.006 · Cited by 148 · see citing works

Targeting IRAK4 for Degradation with PROTACs

Nunes, J., McGonagle, G. A., Eden, J., Kiritharan, G., Touzet, M., Lewell, X., Emery, J., Eidam, H., Harling, J. D., & Anderson, N. A. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00219 · Cited by 134 · see citing works

B-cell–specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice

Knittel, G., Liedgens, P., Korovkina, D., Seeger, J. M., Al-Baldawi, Y., Al-Maarri, M., Fritz, C., Vlantis, K., Bezhanova, S. D., Scheel, A. H., et al. (2016) · Blood · doi:10.1182/blood-2015-11-684183 · Cited by 120 · see citing works

Roles of the TRAF6 and Pellino E3 ligases in MyD88 and RANKL signaling

Strickson, S., Emmerich, C. H., Goh, E. T. H., Zhang, J., Kelsall, I. R., Macartney, T., Hastie, C. J., Knebel, A., Peggie, M. W., Marchesi, F., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1702367114 · Cited by 120 · see citing works

Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4

Powers, J. P., Li, S., Jaén, J. C., Liu, J., Walker, N. P. C., Wang, Z., & Wesche, H. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.03.020 · Cited by 118 · see citing works

MYD88 L265P Somatic Mutation in IgM MGUS

Landgren, O., & Staudt, L. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmc1211959 · Cited by 103 · see citing works

Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations

Yamada, S., Ishida, Y., Matsuno, A., & Yamazaki, K. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.979413 · Cited by 89 · see citing works

Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88L265P Diffuse Large B-Cell Lymphoma

Scott, J. S., Degorce, S. L., Anjum, R., Culshaw, J. D., Davies, R. D. M., Davies, N. L., Dillman, K. S., Dowling, J. E., Drew, L., Ferguson, A. D., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01290 · Cited by 58 · see citing works

Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors: an updated patent review (2016-2018)

McElroy, W. T. (2019) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2019.1597850 · Cited by 57 · see citing works

Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia

Giménez, N., Schulz, R., Higashi, M., Aymerich, M., Villamor, N., Delgado, J., Juan, M., López‐Guerra, M., Campo, E., Rosich, L., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0507-8 · Cited by 53 · see citing works

Extracellular vesicle–mediated transfer of constitutively active MyD88L265P engages MyD88wt and activates signaling

Manček‐Keber, M., Lainšček, D., Benčina, M., Chen, J. G., Romih, R., Hunter, Z. R., Treon, S. P., & Jerala, R. (2018) · Blood · doi:10.1182/blood-2017-09-805499 · Cited by 46 · see citing works

IRAK‐4 kinase activity is required for IRAK‐4‐dependent innate and adaptive immune responses

Lye, E., Dhanji, S., Calzascia, T., Elford, A. R., & Ohashi, P. S. (2008) · European Journal of Immunology · doi:10.1002/eji.200737429 · Cited by 43 · see citing works

Oncogenic MYD88 mutations in lymphoma: novel insights and therapeutic possibilities

Weber, A. N. R., Gloria, Y. C., Çınar, Ö., Reinhardt, H. C., Pezzutto, A., & Wolz, O. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2242-9 · Cited by 35 · see citing works

Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015)

Seganish, W. M. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2016.1202926 · Cited by 30 · see citing works

Efforts towards the optimization of a bi-aryl class of potent IRAK4 inhibitors

Hanisak, J., Seganish, W. M., McElroy, W. T., Tang, H., Zhang, R., Tsui, H., Fischmann, T., Tulshian, D., Tata, J. R., Sondey, C., et al. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.07.048 · Cited by 20 · see citing works

First report of MYD88L265P somatic mutation in IgM-associated light-chain amyloidosis

Chakraborty, R., Novak, A. J., Ansell, S. M., Muchtar, E., Kapoor, P., Hayman, S. R., Dispenzieri, A. A., Buadi, F. K., Lacy, M. Q., King, R. L., et al. (2016) · Blood · doi:10.1182/blood-2016-02-702035 · Cited by 19 · see citing works

Initial optimization and series evolution of diaminopyrimidine inhibitors of interleukin-1 receptor associated kinase 4

Seganish, W. M., McElroy, W. T., Herr, R. J., Brumfield, S., Greenlee, W. J., Harding, J., Komanduri, V., Matasi, J. J., Prakash, K. C., Tulshian, D., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.05.097 · Cited by 10 · see citing works

PROTAC targeted protein degraders: the past is prologue

Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395 · see citing works

Targeted protein degradation: mechanisms, strategies and application

Zhao, L., Zhao, J., Zhong, K., Tong, A., & Jia, D. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00966-4 · Cited by 986 · see citing works

Targeted protein degradation: from mechanisms to clinic

Tsai, J. M., Nowak, R. P., Ebert, B. L., & Fischer, E. S. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00729-9 · Cited by 438 · see citing works

Proteolysis-targeting chimeras (PROTACs) in cancer therapy

Li, X., Pu, W., Zheng, Q., Ai, M., Chen, S., & Peng, Y. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01434-3 · Cited by 374 · see citing works

An overview of PROTACs: a promising drug discovery paradigm

Zi, L., Hu, M., Yu, Y., Du, C., Zhou, H., Liu, C., Chen, Y., Fan, L., Ma, H., Gong, Y., et al. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00112-0 · Cited by 366 · see citing works

Targeted protein degradation: advances in drug discovery and clinical practice

Zhong, G., Chang, X., Xie, W., & Zhou, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02004-x · Cited by 326 · see citing works

PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)

He, M., Cao, C., Ni, Z., Liu, Y., Song, P., Hao, S., He, Y., Sun, X., & Rao, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00999-9 · Cited by 283 · see citing works

Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins

Pance, K., Gramespacher, J. A., Byrnes, J. R., Salangsang, F., Serrano, J.-A. C., Cotton, A. D., Steri, V., & Wells, J. A. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01456-2 · Cited by 265 · see citing works

Developments of CRBN-based PROTACs as potential therapeutic agents

Wang, C., Zhang, Y., Wu, Y., & Xing, D. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113749 · Cited by 152 · see citing works

IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies

Bennett, J., & Starczynowski, D. T. (2021) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000693 · Cited by 100 · see citing works

Recent Advances in PROTACs for Drug Targeted Protein Research

Yao, T., Xiao, H., Wang, H., & Xu, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810328 · Cited by 78 · see citing works

E3 ligase ligand optimization of Clinical PROTACs

Jiang, H., Xiong, H., Gu, S.-X., & Wang, M. (2023) · Frontiers in Chemistry · doi:10.3389/fchem.2023.1098331 · Cited by 61 · see citing works

Targeting cereblon in hematologic malignancies

Fuchs, O. (2023) · Blood Reviews · doi:10.1016/j.blre.2022.100994 · Cited by 55 · see citing works

Optimization of PROTAC Ternary Complex Using DNA Encoded Library Approach

Chen, Q., Liu, C., Wang, W., Meng, X., Cheng, X., Li, X.-Y., Cai, L., Luo, L., He, X., Qu, H., et al. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.2c00797 · Cited by 55 · see citing works

Targeting the Non-Catalytic Functions: a New Paradigm for Kinase Drug Discovery?

Wang, Z., Huang, W., Zhou, K., Ren, X., & Ding, K. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01978 · Cited by 52 · see citing works

Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B-Cell Lymphoma

Weiss, M. M., Zheng, X., Ji, N., Browne, C. M., Campbell, V. T., Chen, D., Enerson, B., Fei, X., Huang, X., Klaus, C. R., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01823 · Cited by 51 · see citing works

The recent advance of Interleukin-1 receptor associated kinase 4 inhibitors for the treatment of inflammation and related diseases

Bai, Y., Yang, W., Hou, X., Shen, D., Zhang, S., Li, N., Qiao, Y.-Y., Wang, S., Yuan, S., & Liu, H. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115606 · Cited by 50 · see citing works

Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents

Wang, C., Zhang, Y., Shi, L., Yang, S., Chang, J., Zhong, Y., Li, Q., & Xing, D. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2074414 · Cited by 49 · see citing works

Unlocking the potential of PROTACs: A comprehensive review of protein degradation strategies in disease therapy

Bhole, R. P., Kute, P. R., Chikhale, R. V., Bonde, C. G., Pant, A. M., & Gurav, S. S. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106720 · Cited by 48 · see citing works

Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery

Xi, J., Zhang, R., Chen, K., Yao, L., Li, M., Jiang, R., Li, X., & Fan, L. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105848 · Cited by 45 · see citing works

A novel IRAK4/PIM1 inhibitor ameliorates rheumatoid arthritis and lymphoid malignancy by blocking the TLR/MYD88-mediated NF-κB pathway

Yoon, S.-B., Hong, H., Lim, H.-J., Choi, J. H., Choi, Y. P., Seo, S. W., Lee, H. W., Chae, C. H., Park, W.-K., Kim, H. Y., et al. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.12.001 · Cited by 44 · see citing works

Targeted Protein Degradation (TPD) for Immunotherapy: Understanding Proteolysis Targeting Chimera-Driven Ubiquitin-Proteasome Interactions

Kamaraj, R., Ghosh, S., Das, S., Sen, S., Kumar, P. R., Majumdar, M., Dasgupta, R., Mukherjee, S., Das, S., Ghose, I., et al. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00253 · Cited by 37 · see citing works

PROTACs technology for targeting non-oncoproteins: Advances and perspectives

Wang, C., Zhang, Y., Xing, D., & Zhang, R. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105109 · Cited by 31 · see citing works

Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): Kinase inhibitors

Zheng, J., Wu, J., Ding, X., Shen, H. C., & Zou, G. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.127862 · Cited by 29 · see citing works

Discovery of Highly Potent and Selective IRAK1 Degraders to Probe Scaffolding Functions of IRAK1 in ABC DLBCL

Fu, L., Zhang, J., Shen, B., Kong, L., Liu, Y., Tu, W., Wang, W., Cai, X., Wang, X., Cheng, N., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00103 · Cited by 29 · see citing works

PROTAC unleashed: Unveiling the synthetic approaches and potential therapeutic applications

Pravin, N., & Jóźwiak, K. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116837 · Cited by 28 · see citing works

Recent insights of PROTAC developments in inflammation-mediated and autoimmune targets: a critical review

Galla, M. S., Sharma, N., Mishra, P., & Shankaraiah, N. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00142g · Cited by 24 · see citing works

Developments of PROTACs technology in immune-related diseases

Wang, C., Zhang, Y., Deng, J., Liang, B., & Xing, D. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115127 · Cited by 23 · see citing works

The Peptide PROTAC Modality: A New Strategy for Drug Discovery

Zhu, Y., Dai, Y., & Tian, Y. (2025) · MedComm · doi:10.1002/mco2.70133 · Cited by 23 · see citing works

Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges

Wang, C., Zhang, Y., Zhang, T., Shi, L., Geng, Z., & Xing, D. (2022) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2022.2076675 · Cited by 21 · see citing works

ITK degradation to block T cell receptor signaling and overcome therapeutic resistance in T cell lymphomas

Jiang, B., Weinstock, D. M., Donovan, K. A., Sun, H.-W., Wolfe, A., Amaka, S., Donaldson, N. L., Wu, G., Jiang, Y. Z., Wilcox, R. A., et al. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.03.007 · Cited by 19 · see citing works

Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors

Guidetti, F., Arribas, A. J., Sartori, G., Spriano, F., Barnabei, L., Tarantelli, C., von Roemeling, R., Martinez, E. M., Zucca, E., & Bertoni, F. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12020399 · Cited by 17 · see citing works

Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) Degraders for Treating Inflammatory Diseases: Advances and Prospects

Lin, Y., Zheng, L., Xu, Y., Wang, X., Li, J., Zheng, L., Liang, G., & Chen, L. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01322 · Cited by 13 · see citing works

Fragment-Based Anti-inflammatory Agent Design and Target Identification: Discovery of AF-45 as an IRAK4 Inhibitor to Treat Ulcerative Colitis and Acute Lung Injury

Zou, Y., Wang, X., Chen, P., Zheng, Z., Li, X., Chen, Z., Guo, M., Zhou, Y., Sun, C., Wang, R., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00202 · Cited by 13 · see citing works

Discovery of the First Clinical Protein Degrader for the Treatment of Autoimmune Indications: Orally Bioavailable and Selective IRAK4 Degrader KT-474

Edmondson, S. D. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02264 · Cited by 13 · see citing works

The application of PROTACs in immune-inflammation diseases

Zhang, C., Sun, X., Song, P., & Rao, Y. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117967 · Cited by 12 · see citing works

Discovery of Rigid Linker-Based IRAK4 PROTACs with Improved Metabolic Stability for the Treatment of Inflammatory Diseases

Fan, Y., Ma, R., Njobvu, K. M., Wang, Y., Ren, Y., Fu, R., Zhang, C., Liu, F., Jiang, Z., Rao, Y., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01620 · Cited by 11 · see citing works

A small molecule potent IRAK4 inhibitor abrogates lipopolysaccharide-induced macrophage inflammation in-vitro and in-vivo

Choudhary, S. A., Patra, D., Sinha, A., Mazumder, S., Pant, R., Chouhan, R., Jha, A. N., Prusty, B. M., Manna, D., Das, S., et al. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175593 · Cited by 11 · see citing works

Modulation of expression of proinflammatory genes and humoral immune response following immunization or infection with Aeromonas hydrophila in silver catfish (Rhamdia quelen)

Soveral, L. D. F., de Almeida, P. A., Kreutz, Y., Ribeiro, V. A., Frandoloso, R., & Kreutz, L. C. (2022) · Fish and Shellfish Immunology Reports · doi:10.1016/j.fsirep.2022.100053 · Cited by 9 · see citing works

Discovery of LC-MI-3: A Potent and Orally Bioavailable Degrader of Interleukin-1 Receptor-Associated Kinase 4 for the Treatment of Inflammatory Diseases

Chen, L., Luo, R., Ma, L., Xu, Y., Cao, J., Jiang, Z. R., Chen, S., Huang, X., Zhang, M., Zheng, L., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00181 · Cited by 8 · see citing works

MYD88L265P augments proximal B-cell receptor signaling in large B-cell lymphomas via an interaction with DOCK8

Mandato, E., Yan, Q., Ouyang, J., Paczkowska, J., Qin, Y., Hao, Y., Bojarczuk, K., Hansen, J., Chapuy, B., Rodig, S. J., et al. (2023) · Blood · doi:10.1182/blood.2023019865 · Cited by 8 · see citing works

IRAK signaling in cancers: mechanisms, targeting, and clinical implications

Vick, E. J., & Starczynowski, D. T. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2573646 · Cited by 5 · see citing works

Lasalocid A selectively induces the degradation of MYD88 in lymphomas harboring the MYD88 L265P mutation

Li, W., Wang, R., Wang, J., Chai, D., Xie, X., Young, K. H., Cao, Y., Li, Y., & Yu, X. (2024) · Blood · doi:10.1182/blood.2024026781 · Cited by 5 · see citing works

Advances in proteomics in diffuse large B‑cell lymphoma (Review)

Guo, Z., Wang, C., Shi, X., Wang, Z., Tao, J., Ma, J., & Bi, L. (2024) · Oncology Reports · doi:10.3892/or.2024.8746 · Cited by 3 · see citing works

Application of PROTAC Technology in Drug Development

Kharkar, P. S., & Jadhav, A. L. (2022) · Methods and principles in medicinal chemistry · doi:10.1002/9783527827855.ch10 · Cited by 2 · see citing works

Degradation of IRAK4 for the treatment of lipopolysaccharide-induced acute lung injury in mice

Ye, B., Chen, S., Huang, X., Qiu, Y., Luo, R., & Zheng, L. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1609923 · Cited by 1 · see citing works

A novel proteolysis-targeting chimera strategy targeting multiple immune checkpoints containing ITIMs enhances antitumor immunity

Qiu, Y.-Y., Wang, Z., He, L., Shi, G.-G., Li, Z.-Z., Ma, S.-X., Yu, D. N., Du, H., Xie, F., Zhang, C., et al. (2025) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2025.101511 · Cited by 1 · see citing works

Broadening the horizon: The promise of PROTACs in non-malignant disorders

Fu, L., Zeng, G., Cao, Y., He, Y., Zhao, Y., Tian, C., Chen, J., Feng, H., Xi, J., Shao, J., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118586 · Cited by 1 · see citing works

Stimulated protein degradation to promote mitochondrial function and neuronal survival

Chandrasekhar, S., McMinimy, R. A., Manford, A. G., Wehri, E., Gee, C. L., Miller, C., Bingol, B., Kuriyan, J., Schaletzky, J., & Rapé, M. (2026) · Science · doi:10.1126/science.aed2525 · Cited by 1 · see citing works

The Future of Heterobifunctional Compounds: PROTACs and Beyond

Burslem, G. M. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch10

Destruction with a Purpose: Targeted Protein Degradation in Drug Discovery

Martinelli, P., Kofink, C. C., Boeck, G., Weinstabl, H., & Koegl, M. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch11

HETEROBIFUNCTIONAL DEGRADERS OF IRAK4 FOR AUTOIMMUNE INDICATIONS

Weiss, M. M. (2024) · Medicinal chemistry reviews · doi:10.1021/mc-2024-vol59.ch06

Protease-mediated degradation

Yang, L., Duan, H., Mao, X., Li, B., Che, J., & Dong, X. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-21816-3.00004-x

Proteolysis Targeting Chimeric-Based Technology in Myeloma and Lymphoma

Țigu, A. B., Ivancuta, A., Tomuleasa, C., Nistor, M., Kegyes, D., Cenariu, D., Munteanu, R. A., Buzoianu, A. D., Einsele, H., Federico, M., et al. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-25-1148

PROTACs: Next-generation cancer therapeutics revolutionizing targeted treatment strategies

Sireen, U., Thota, S., Amreen, N., Kumaraswamy, D., Katherashala, S., & Sriram, S. (2026) · In Silico Research in Biomedicine · doi:10.1016/j.insi.2026.100386

Development of APH003─a Highly Potent, Selective, and Orally Bioavailable IRAK4 PROTAC Degrader for the Treatment of Inflammatory Diseases

Wu, X., Chen, Z.-M., Gao, C., Tian, M., Liu, X.-L., Wang, H., Chen, H.-J., Li, H.-X., Yang, W.-Q., & An, L. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00828

BindingDB Entry 50021364: Discovery of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates Targeting MYD88 Mutant Diffuse Large B-Cell Lymphoma.

BindingDB (2025) · UC San Diego · doi:10.7270/q23f4v8g

BindingDB Entry 50021077: Discovery of LC-MI-3: A Potent and Orally Bioavailable Degrader of Interleukin-1 Receptor-Associated Kinase 4 for the Treatment of Inflammatory Diseases.

BindingDB (2025) · UC San Diego · doi:10.7270/q2pc370n

BindingDB Entry 50021924: Recent insights of PROTAC developments in inflammation-mediated and autoimmune targets: a critical review.

BindingDB (2025) · UC San Diego · doi:10.7270/q2pz5fhg

BindingDB Entry 50014745: Discovery of Highly Potent and Selective IRAK1 Degraders to Probe Scaffolding Functions of IRAK1 in ABC DLBCL.

BindingDB (2023) · UC San Diego · doi:10.7270/q2ms3xmh

BindingDB Entry 50018659: Developments of CRBN-based PROTACs as potential therapeutic agents.

BindingDB (2024) · UC San Diego · doi:10.7270/q27948wc

BindingDB Entry 50019825: Developments of PROTACs technology in immune-related diseases.

BindingDB (2024) · UC San Diego · doi:10.7270/q2cr5zrz

BindingDB Entry 50022935: Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) Degraders for Treating Inflammatory Diseases: Advances and Prospects.

BindingDB (2026) · UC San Diego · doi:10.7270/q2zg6z3b

BindingDB Entry 50021363: Fragment-Based Anti-inflammatory Agent Design and Target Identification: Discovery of AF-45 as an IRAK4 Inhibitor to Treat Ulcerative Colitis and Acute Lung Injury.

BindingDB (2025) · UC San Diego · doi:10.7270/q2765kzb

BindingDB Entry 50023478: PROTAC unleashed: Unveiling the synthetic approaches and potential therapeutic applications.

BindingDB (2026) · UC San Diego · doi:10.7270/q2kp8732

BindingDB Entry 50012415: Small molecule approaches to treat autoimmune and inflammatory diseases (Part I): Kinase inhibitors.

BindingDB (2022) · UC San Diego · doi:10.7270/q21v5jnk

BindingDB Entry 50022400: The recent advance of Interleukin-1 receptor associated kinase 4 inhibitors for the treatment of inflammation and related diseases.

BindingDB (2025) · UC San Diego · doi:10.7270/q2z89j3f

Discovery of Highly Potent and Selective IRAK1 Degraders to Probe Scaffolding Functions of IRAK1 in ABC DLBCL

Fu, L., Zhang, J., Shen, B., Kong, L., Liu, Y., Tu, W., Wang, W., Cai, X., Wang, X., Cheng, N., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00103 · Cited by 29 · see citing works

Design, Synthesis, and Biological Evaluation of IRAK4-Targeting PROTACs

Chen, Y., Ning, Y., Bai, G., Tong, L., Zhang, T., Zhou, J., Zhang, H., Xie, H., Ding, J., & Duan, W. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00474 · Cited by 49 · see citing works

Emerging trends in IRAK-4 kinase research

Yadav, H. K., & Shirumalla, R. K. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08438-w · Cited by 15 · see citing works

IRAK4 Kinase As A Novel Therapeutic Target in the ABC Subtype of Diffuse Large B Cell Lymphoma

Lim, K.-H., Romero, D. L., Chaudhary, D., Robinson, S. D., & Staudt, L. M. (2012) · Blood · doi:10.1182/blood.v120.21.62.62 · Cited by 21 · see citing works

Abstract 4798: Efficacy and safety of highly selective novel IRAK4 inhibitors for treatment of ABC-DLBCL

Balasubramanian, W. R., Gummadi, V. R., Nellore, K., Mukherjee, S., Marappan, S., Basavaraju, A., Ainan, B. R., Daginakatte, G., Gopinath, S., Giri, S., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-4798 · Cited by 1 · see citing works